Zenas BioPharma, Inc.
ZBIO
$25.87
$1.204.86%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
10/31/2025
-
MarketBeat
6/26/2026
-
TipRanks
6/21/2026
-
Nasdaq News: Markets
6/21/2026
-
Fool.com Headlines
6/18/2026
-
The Cerbat Gem
6/18/2026
-
MarketBeat
6/17/2026
-
Globe Newswire
6/17/2026
-
MarketBeat
6/15/2026
-
The Cerbat Gem
6/14/2026
-
MarketBeat
6/14/2026
-
Simply Wall St
6/12/2026
-
Morningstar
6/11/2026
-
Globe Newswire
6/8/2026
-
Simply Wall St
How Positive Phase 3 Obexelimab Data and FDA BLA Filing Will Impact Zenas BioPharma (ZBIO) Investors
6/4/2026
-
Simply Wall St
5/30/2026
-
Simply Wall St
5/28/2026
-
Globe Newswire
5/24/2026
-
Simply Wall St
5/21/2026
-
The Cerbat Gem
5/19/2026
-
Nasdaq News: Markets
5/19/2026
-
MarketBeat
5/19/2026
-
Globe Newswire
5/18/2026
-
Globe Newswire
10/28/2025
-
MarketBeat
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Wednesday, May 13, 2026
Period Date
Tuesday, March 31, 2026
Next Filing
Week of Aug 10 and 14 (est)
Price History
Beta
--
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
857 271 2954
Address
852 Winter Street
Waltham, MA 02451
Waltham, MA 02451
Country
Year Founded
Business Description
Sector
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab...
more